4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products Emeryville, CA, April 30, 2018  — 4D Molecular Therapeutics (4DMT), a leader in  Therapeutic Vector Evolution  for adeno-associated virus (AAV) gene therapy vector discovery and product

New  Funding Brings Total IND-Enabling Research and Development Support for 4D-710 to over $3.5 Million Emeryville, CA  — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced $3 million in additional